{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-22-000108","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.679873+00:00","generated_at":"2026-06-21T15:39:17.480538+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics earns $60M milestone from Provention on FDA approval of teplizumab","bullets":["FDA approved teplizumab BLA for type 1 diabetes; MacroGenics receives $60M milestone from Provention.","Total potential regulatory milestones from Provention up to $170M; additional $225M in sales milestones.","Single-digit royalty on net sales of teplizumab payable to MacroGenics.","Cash runway extended into late 2024 based on existing cash and anticipated partner payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-22-000108","json":"https://secwatch.observer/filing/0001125345-22-000108.json","markdown":"https://secwatch.observer/filing/0001125345-22-000108.md","text":"https://secwatch.observer/filing/0001125345-22-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000108/0001125345-22-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000108/mgnx-20221117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:39:17.480538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}